Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.80.

IMUX has been the subject of several analyst reports. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Leerink Partners restated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a report on Monday, September 16th. Finally, HC Wainwright began coverage on Immunic in a research note on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock.

Insiders Place Their Bets

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of Immunic stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Immunic during the 3rd quarter worth about $50,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the period. Finally, State Street Corp raised its position in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $1.05 on Wednesday. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11. The business has a fifty day moving average price of $1.23 and a 200 day moving average price of $1.33. The stock has a market capitalization of $94.58 million, a P/E ratio of -0.85 and a beta of 1.89.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.